

# PHARMACY UPDATE

## Medicaid Pharmacy Drug Utilization Review (DUR) Program Update

**Effective November 29, 2012**, the fee-for-service pharmacy program will implement the following parameters which include step therapy and frequency/quantity/duration (F/Q/D) requirements. These changes are the result of recommendations made by the Drug Utilization Review Board (DURB) at the September 6, 2012, DURB meeting.

### **Treatment of Type 2 Diabetes – Metformin**

- Require a trial with metformin with or without insulin prior to initiating other antidiabetic agents (unless documented contraindication).

### **Treatment of Type 2 Diabetes – Glucagon-Like Peptide-1 (GLP-1) Agonists**

- Require a trial with metformin plus another oral antidiabetic agent prior to a GLP-1 agonist (Prior authorization requirement with lack of covered diagnosis in medical history).

### **Treatment of Diabetic Peripheral Neuropathy (DPN)**

- Require a trial with a tricyclic antidepressant **OR** gabapentin prior to duloxetine and pregabalin (for treatment of DPN).

### **Teriparatide (Forteo)**

- Require a trial with a preferred oral bisphosphonate prior to teriparatide.
- Quantity limit of one unit (2.4 mL) per 30 day period with a lifetime quantity limit of 25 months of therapy.

### **Anti-Retroviral (ARV) Interventions**

- Limit ARV active ingredient duplication.
- Limit ARV utilization to a maximum of five products concurrently - excluding boosting with ritonavir (dose limit 600 mg or less) or cobicistat.
- Limit Protease Inhibitor utilization to a maximum of two products concurrently.

### **Hepatitis-C Treatment in HCV/HIV Co-Infection**

- Minimum quantity limit of 9 (nine) tablets of telaprevir per day for beneficiaries receiving efavirenz.

-continued-